1. Home
  2. NVCR vs DKL Comparison

NVCR vs DKL Comparison

Compare NVCR & DKL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NVCR
  • DKL
  • Stock Information
  • Founded
  • NVCR 2000
  • DKL 2012
  • Country
  • NVCR Switzerland
  • DKL United States
  • Employees
  • NVCR N/A
  • DKL N/A
  • Industry
  • NVCR Medical/Dental Instruments
  • DKL Natural Gas Distribution
  • Sector
  • NVCR Health Care
  • DKL Energy
  • Exchange
  • NVCR Nasdaq
  • DKL Nasdaq
  • Market Cap
  • NVCR 1.9B
  • DKL 2.3B
  • IPO Year
  • NVCR 2015
  • DKL N/A
  • Fundamental
  • Price
  • NVCR $17.55
  • DKL $44.14
  • Analyst Decision
  • NVCR Buy
  • DKL Buy
  • Analyst Count
  • NVCR 7
  • DKL 4
  • Target Price
  • NVCR $32.43
  • DKL $44.25
  • AVG Volume (30 Days)
  • NVCR 1.3M
  • DKL 87.3K
  • Earning Date
  • NVCR 07-24-2025
  • DKL 08-05-2025
  • Dividend Yield
  • NVCR N/A
  • DKL 10.07%
  • EPS Growth
  • NVCR N/A
  • DKL 7.97
  • EPS
  • NVCR N/A
  • DKL 2.98
  • Revenue
  • NVCR $621,711,000.00
  • DKL $938,491,000.00
  • Revenue This Year
  • NVCR $5.56
  • DKL $21.09
  • Revenue Next Year
  • NVCR $9.19
  • DKL N/A
  • P/E Ratio
  • NVCR N/A
  • DKL $14.80
  • Revenue Growth
  • NVCR 18.27
  • DKL N/A
  • 52 Week Low
  • NVCR $14.17
  • DKL $34.59
  • 52 Week High
  • NVCR $34.13
  • DKL $45.71
  • Technical
  • Relative Strength Index (RSI)
  • NVCR 48.98
  • DKL 60.61
  • Support Level
  • NVCR $16.81
  • DKL $43.63
  • Resistance Level
  • NVCR $18.59
  • DKL $44.64
  • Average True Range (ATR)
  • NVCR 0.70
  • DKL 0.79
  • MACD
  • NVCR 0.04
  • DKL 0.03
  • Stochastic Oscillator
  • NVCR 44.93
  • DKL 81.06

About NVCR NovoCure Limited

NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

About DKL Delek Logistics Partners L.P. Common Units representing Limited Partner Interests

Delek Logistics Partners LP owns and operates logistics and marketing assets for crude oil and intermediate and refined products. The company's segment includes gathering and processing; wholesale marketing and terminalling; storage and transportation and investment in pipeline joint ventures. It generates maximum revenue from the wholesale marketing and terminalling segment, which provides marketing services for the refined products output of the Delek Holdings' refineries, engages in wholesale activity at its terminals and terminals owned by third parties, whereby it purchases light product for sale and exchange to third parties, and provides terminalling services at its refined products terminals to independent third parties and Delek Holdings.

Share on Social Networks: